We then examined whether RIPK1-dependent cell death participates in the rejection of grafts exposed to prolonged CIS using necrostatin-1, a small molecule that inhibits the kinase activity of RIPK1 previously shown by others to prevent programmed cell death (51). The gene discussed is RIPK1; the disease is in situ carcinoma.